electroCore (ECOR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Jul, 2026Executive summary
Annual Meeting scheduled for September 8, 2026, will be held virtually, with voting on three key proposals: election of directors, ratification of auditors, and a say-on-pay advisory vote.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact, with printed copies available upon request.
Only stockholders of record as of July 10, 2026, are entitled to vote; 9,015,885 shares are outstanding and eligible.
Forward-looking statements are included, cautioning about risks and uncertainties affecting future results.
Voting matters and shareholder proposals
Proposal 1: Elect three Class II directors (Errico, Theofilos, Bonfiglioli) for terms expiring in 2029.
Proposal 2: Ratify CBIZ CPAs P.C. as independent auditors for fiscal year 2026.
Proposal 3: Approve, by non-binding advisory vote, named executive officer compensation.
Board recommends voting FOR all proposals.
Voting can be done online, by phone, mail, or during the virtual meeting; abstentions and broker non-votes affect outcomes as described.
Board of directors and corporate governance
Board reduced from seven to six members after a resignation in 2026; directors are divided into three classes with staggered three-year terms.
All directors are deemed independent under Nasdaq and SEC rules.
Board has an independent chairman and three standing committees: audit, compensation, and nominating/governance.
Board and committees met regularly in 2025, with high attendance and executive sessions held without management.
Board skills matrix highlights expertise in governance, risk, technology, finance, and life sciences.
Board diversity in age, tenure, and professional background is emphasized.
Latest events from electroCore
- Q2 sales hit $6.1M, margin rose to 86%, and $9M was raised, led by VA/DoD and Truvaga growth.ECOR
Q2 20248 Jul 2026 - Q3 revenue up 45% year-over-year, net loss narrows, and cash position strengthens.ECOR
Q3 20248 Jul 2026 - Q1 2025 revenue up 23% to $6.7M; NeuroMetrix acquired; gross margin 85%; $30M FY outlook.ECOR
Q1 202530 Jun 2026 - Q1 2026 revenue up 43% to $9.6M, with improved margins but ongoing net loss and liquidity risks.ECOR
Q1 202626 Jun 2026 - 2024 revenue up 57% to $25.2M, gross margin 85%, and net loss narrowed by 37% to $11.9M.ECOR
Q4 202426 Jun 2026 - Rapid growth, expanding markets, and platform innovation drive strong financial outlook.ECOR
IAccess Alpha Virtual Best Ideas Summer Investment Conference 202623 Jun 2026 - Strong growth in federal markets and new product launches drive expansion and margin gains.ECOR
Planet MicroCap Las Vegas 202617 Jun 2026 - Rapid growth, unique vagus nerve tech, and new partnerships drive future expansion.ECOR
16th Annual LD Micro Invitational Conference18 May 2026 - Bioelectronic medicine leader with rapid growth, FDA-cleared devices, and expanding wellness portfolio.ECOR
Corporate presentation25 Mar 2026